Gilead Sciences News
News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.
5 hrs ago | AmericanBankingNews.com
The firm currently has a "buy" rating on the stock. Deutsche Bank's price objective suggests a potential upside of 82.78% from the company's current price.
Trending on the Topix Network
11 hrs ago | New Hampshire Public Radio -
The launch of Sovaldi, the $1,000-a-day pill for hepatitis C, is shaping up as the most successful ever.
15 hrs ago | Jerusalem Post
Investing.com - U.S. stock futures pointed to a slightly lower open on Wednesday, as investors remained cautious ahead of U.S. economic reports, as well as a fresh batch of first quarter earnings reports to be released later in the day.
19 hrs ago | Seeking Alpha
Welcome to the Gilead Sciences' first quarter 2014 earnings conference call. I would now like to turn the call over to Patrick O'Brien, Vice President of Investor Relations.
Today: Gilead Sciences demolishes earnings expectations thanks to powerful sales of breakthrough hepatitis C drug Sovaldi.
Orlando Chavez, fills a work station inside a mobile medical outreach van operated by the Berkeley Free Clinic, on Thursday April 10, 2014, in Berkeley, Calif., which does weekly on-the-street medical testing, including Hepatitis C. Chavez who was diagnosed with Hepatitis C in 1999 and underwent treatment successfully in 2004-2005, is now cured and ... (more)
Gilead Sciences, Inc. announced today its results of operations for the quarter ended March 31, 2014.
Gilead Sciences is among the big biotech companies that have seen their shares whipsaw in the recent sell-off in biotech stocks .
Gilead Sciences' New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA FOSTER CITY, Calif.-- Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has accepted the company's refiling of two New Drug Applications for cobicistat, a pharmacoenhancing or "boosting" agent that increases ... (more)
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has accepted the company's refiling of two New Drug Applications for cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of the protease inhibitors atazanavir and darunavir to enable once-daily dosing of these medicines in HIV therapy, and ... (more)
Sunrise wil... )--Werner Enterprises, Inc. , one of the nation's largest transportation and logistics companies, reported revenues and earnings for the first quarter ended... )--Link to Fitch Ratings' Report: Fitch US RMBS Servicer Snapshot Reporthttp://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=747112 Fitch Ratings has ... (more)
One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences ' highly effective hepatitis C therapy.
When Foster City, Calif.-based Gilead Sciences was developing its hepatitis C treatment, Sovaldi, the medical community was wowed by the 90% cure rate the drug racked up in clinical trials.